What's Happening?
Merck Animal Health, a division of Merck & Co., Inc., has announced a definitive agreement to acquire TARGAN, a company specializing in innovative biodevice solutions for the poultry industry. This acquisition aims to enhance Merck's portfolio in commercial
poultry operations by incorporating TARGAN's WingScan™, a high-speed vision technology that identifies and sorts chicks by gender. The technology processes up to 160,000 chicks per hour and is scalable to any hatchery size. The acquisition, expected to close in the third quarter of 2026, will also bring high-speed precision ocular spray technology for administering vaccines to day-old chicks. TARGAN, founded in 2015 and based in Raleigh, North Carolina, focuses on transforming animal protein production with individualized technologies that improve speed, accuracy, and animal welfare.
Why It's Important?
The acquisition of TARGAN by Merck Animal Health is significant as it represents a strategic expansion of Merck's capabilities in the animal health sector, particularly in poultry operations. By integrating TARGAN's advanced technologies, Merck aims to deliver enhanced value to its customers through improved efficiency and animal welfare. This move could potentially set new standards in the industry by providing scalable solutions that address both economic and ethical concerns in animal farming. The acquisition also underscores the growing importance of technology in agriculture, as companies seek to innovate and improve productivity while maintaining sustainable practices.
What's Next?
Following the acquisition, Merck Animal Health plans to leverage TARGAN's resources and infrastructure to deploy its innovative biodevice technology alongside Merck's existing portfolio of poultry vaccines. This integration is expected to create new opportunities for Merck in the animal health industry, potentially leading to further advancements in biodevice development across various livestock species. Regulatory approvals and customary closing conditions are anticipated to be completed by the third quarter of 2026, paving the way for the full implementation of TARGAN's technologies within Merck's operations.
